How Can Investors Benefit from Pfizer's Dividend Yield for a Monthly Income?
Pfizer Inc. (NYSE: PFE) shares remained relatively stable on Friday, but experienced a decline of around 44% throughout 2023.
Recently, Pfizer announced the successful completion of its acquisition of Seagen Inc (NASDAQ: SGEN) for a total value of approximately $43 billion, at a price of $229 per share.
The company has also provided its full-year 2024 guidance, taking into account the financial impact of the Seagen transaction. For the fiscal year 2024, Pfizer expects revenue in the range of $58.5 billion to $61.5 billion, including the expected contribution from the Seagen acquisition. This projection falls slightly below the consensus estimate of $63.17 billion.
Given the current buzz surrounding Pfizer, investors may be considering the potential benefits of the company's dividend yield. Presently, Pfizer offers an attractive annual dividend yield of 5.84%, which translates to a quarterly dividend of 42 cents per share ($1.68 per year).
The question arises: how can investors leverage Pfizer's dividend yield to generate a regular monthly income of $500?
To achieve a monthly income of $500 or an annual income of $6,000 from dividends alone, investors would need to make an approximate investment of $102,809, which would equate to owning around 3,571 shares. On a more modest scale, an investment of approximately $20,556 or around 714 shares would generate a monthly income of $100 or an annual income of $1,200.
It's important to consider that dividend yield can vary as both the dividend payment and the stock price fluctuate over time.
Dividend yield is calculated by dividing the annual dividend payment by the current stock price. For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2 divided by $50). Fluctuations in the stock price can impact the dividend yield. If the stock price increases to $60, the dividend yield drops to 3.33% ($2 divided by $60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2 divided by $40).
Additionally, changes in the dividend payment itself can influence the yield. If a company increases its dividend, the yield will also increase, assuming the stock price remains constant. Conversely, if the dividend payment decreases, the yield will decrease as well.
In summary, Pfizer's dividend yield offers an opportunity for investors to generate a regular monthly income. By carefully considering the dividend yield and the desired income, investors can make informed decisions regarding their investment in Pfizer.
Looking for chemical products? Let suppliers reach out to you!
2026-07-12
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pfizer's Revenue Forecast Disappoints, Stock Plummets: A Closer Look at the Challenges Ahead
-
Pfizer's Angela Hwang Departs as Company Completes Seagen Acquisition and Establishes New Oncology Division
-
2023 Senior Management Personnel Changes of Multinational Pharmaceutical Companies in China, what's behind it? - III
-
Milestone Approvals in Sickle Cell Disease (SCD): FDA Approves Two Therapies before Pfizer's GBT601 Disclosure
-
Pfizer's Strategic Shift in China's Pneumococcal Vaccine Market
-
Pfizer Receives Conditional Approval for Tislelizumab in the Treatment of Relapsed or Refractory Extranodal NK/T-cell Lymphoma (ENKTL)
-
Pfizer: In 2023, COVID-19's product revenue will decline significantly
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
Pfizer acquires biopharmaceutical company Global Blood Therapeutics (GBT)
Recommend Reading
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
Supply Reduction Leads to Slight Rise in Aniline Prices
-
This week, the market price trend of propylene oxide in China has declined (12.15-12.19)
-
High Inventory Triggers Formaldehyde Price Drop
-
In November, PVC Continues to Decline, Market Shows Signs of Stabilization
-
China's Urea Market Trend Rises (12.1-12.18)